An Interventional, Confirmative, Post Marketing Clinical Followup (PMCF) Study to Evaluate Performance and Safety of Ophthalmic Solutions Used to Relieve Dry Eyes Like Symptoms in Glaucoma Patients.
Key facts
- Who runs it
- Montefarmaco OTC SpA
- Where
- Italy2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 59 people enrolled
- Started
- 2 Feb 2022
- Ended
- 24 Dec 2024
- Type of study
- Interventional
- Treatments tested
- Afomill Refreshing Soothing, Afomill Anti-redness Eye Drops, Iridil
- Record updated
- 20 May 2025
- Why it stopped
- Low enrollment rate
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patient Informed consent form (ICF) signed
- M \& F Aged ≥ 18 years at the time of the signature of ICF
- Patients with a prescription, as per clinical practice, of a topic treatment for glaucoma or ocular hypertension (i.e. anti-hypertensive eye drops), showing OSD symptoms (dry eye like symptoms; e.g. burning, redness, fatigue, or irritation sensation)
- Willing not to use other eye drops during the entire treatment period (except for the possible drug-containing glaucoma treatment prescribed as per clinical practice)
Who cannot take part
- Eye surgery during the previous 6 months (e.g. cataract surgery)
- Other - different - eyes clinical conditions
- Known hypersensitivity or allergy to IP components
- Presence of any relevant severe organic, systemic or metabolic disease (particularly significant history of cardiac, renal, neurological, psychiatric, oncology, endocrinology, metabolic or hepatic disease), or abnormal laboratory values that will be deemed clinically significant in Investigator's opinion
- Retinal pathology
- Other type of ophthalmic neuropathy
- Severe POAG
- Participation in another investigational study
- Inability to follow all study procedures, including attending all site visits, tests and examinations
- Mental incapacity that precludes adequate understanding or cooperation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Study Rationale: The glaucomas are a group of optic neuropathies characterized by progressive degeneration of retinal ganglion cells. These are central nervous system neurons that have their cell bodies in the inner retina and axons in the optic nerve.
Read full original descriptionShow less
Degeneration of these nerves results in cupping, a characteristic appearance of the optic disc and visual loss. The biological basis of glaucoma is poorly understood and the factors contributing to its progression have not been fully characterized. Glaucoma affects more than 70 million people worldwide with approximately 10% being bilaterally blind, making it the leading cause of irreversible blindness in the world. Glaucoma can remain asymptomatic until it is severe, resulting in a high likelihood that the number of affected individuals is much higher than the number known to have it.
The tear film is fundamental in the maintenance of the ocular surface. Any condition that adversely affects the stability and function of the tear film such as dry eye symptom, blepharitis, and meibomian gland dysfunction, dysfunctional tear film syndrome, or toxicity of topical medications may result in onset of an ocular surface disease (OSD). The symptoms of OSD may include dryness, burning or stinging, itching, irritation, tearing, photophobia, foreign-body sensation, grittiness, redness, fatigue, fluctuating visual acuity, and blurred vision.
OSD is a common comorbidity in glaucoma patients in part due to the fact thatits prevalence as in glaucoma increases with age. OSD is seen in approximately 15% of the general elderly population and is reported in 48% to 59% of patients with medically treated glaucoma. One in six patients with glaucoma has OSD symptoms severe enough that they need some form of treatment.
Ophthalmic solutions with soothing and refreshing proprieties, as addon treatment to glaucoma therapy, could relieve the OSD symptomatology, dry eye like, in glaucoma patients, improving their quality of life.
For these reasons, an interventional, confirmative, post marketing clinical followup (PMCF) study was planned to evaluate the performance and safety of ophthalmic solutions used to relieve dry eyes like symptoms in glaucoma patients.
Study Objective: The objectives of this PMCF study are confirmation of the performance, collection of additional safety data regarding expected adverse events and detection of potential unexpected adverse events associated with use of three investigational products (IPs).
The IPs are on the market with the following brand names:
* Afomill Refreshing Soothing * Afomill Anti-redness Eye Drops * Iridil
The group in the trial
- Potential candidates, that according the investigator judgment could be treated with one of IPsOther group
At V0, as per clinical practice, only one of the below reported IPs products can be dispensed to the enrolled subject, depending on investigator clinical evaluation and decision: * Afomill Refreshing Soothing * Afomill Anti-redness Eye Drops * Iridil
Treatment: Afomill Refreshing Soothing, Afomill Anti-redness Eye Drops, Iridil
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 20 May 2025